2bind joins CNATM for nucleic acid therapeutics research
2bind is joining the Cluster for Nucleic Acid Therapeutics Munich (CNATM) as an industry partner for the consortium’s second funding period, running from 2026 to 2029. As part of this collaboration, 2bind will contribute to the development of a scalable platform for the production and biophysical characterization of lncRNA-binding proteins, with the goal of identifying and validating protein:RNA complexes as therapeutic targets.
2bind Announces New Co-CEO Leadership Team
2bind GmbH, a leading contract research organization (CRO) specializing in biophysical analysis for drug discovery and antibody development, today announced a transition in its executive leadership. Dr. Thomas Schubert, Co-CEO, has decided to step down from his role, effective October 31, 2024, to pursue other opportunities and dedicate more time to his family.
2bind Opens New Headquarters
2bind GmbH Opens New Headquarters to as a Result of Quality Work and Continued Growth
Dr. Cosimo Kropp joins executive team as CBO
2bind GmbH Elevates Dr. Cosimo Kropp to Chief Business Officer
Dr. Cosimo Kropp Hired as New Director Business Development
2bind GmbH Strengthens Business Development with Appointment of Dr. Cosimo Kropp
2bind Supports Novel Concept Towards Prophylactic HIV-Vaccine
The federally funded interdisciplinary research project “HIVacToGC” was launched to investigate new approaches to the prevention and treatment of HIV infections.
2bind Secures German Federal Funding for Battling Antibiotic Resistance
A consortium of 2bind GmbH and the University of Regensburg have successfully secured over 750.000 EUR federal funding for a research project investigating the potential of glutamine amidotransferase as novel drug targets for antibiotics.
2bind Wins 1st Place in EU-wide Call for Proposals
2bind wins first place in the EU’s Eureka Eurostars competition, together with partners from the Netherlands and Great Britain.
Dr. Maximilian Plach announced as Director Operations & Science
2bind GmbH Appoints Dr. Maximilian Plach as COO to Oversee Rapid Growth
Service Partnership with Assay.Works
2bind GmbH and Assay.Works Join Forces to Expand Drug Discovery Services